Definition: ECLAMC (‘Estudio Colaborativo Latino Americano de Malformaciones Congénitas’) is a program for the clinical and epidemiological investigation of risk factors in the etiology of congenital anomalies in Latin-American hospitals, using a case-control methodological approach. It is a voluntary agreement among professionals lacking institutional base as well as designated budgets. ECLAMC has been usually funded by research-funding agencies rather than public health ministries. The National Research Councils of Argentina and Brazil have been the main sources of support during its 36 years of existence. Since vital and health statistics are unreliable in South America, ECLAMC collects all the information required for the denominators in a hospital-based sample of births. ECLAMC can be defined as a continental network of persons interested in research and prevention of birth defects. History and Evolution: From the institutional point of view, ECLAMC has had headquarters in diverse centers of Argentina and Brazil, but always as an independent research project, without a defined administrative link. ECLAMC began operating in 1967, as an investigation limited to the city of Buenos Aires, Argentina, and it gradually expanded until covering all the 10 countries of South America as well as Costa Rica and the Dominican Republic. Even though ECLAMC has maintained essentially the same original experimental design since 1967, due to the data accumulated by the program, the increasing experience as well as the development in science, technical modifications occurred including a DNA bank and a fully informatized data handling system. Since 1974 ECLAMC has been a founder member of the International Clearinghouse for Birth Defects Monitoring Systems; since 1994 a WHO Collaborating Center for the Prevention of Congenital Malformations, and since 2000 a collaborating member of the NIH Global Netwok for Women’s and Children’s Health Research. Methodology: The maternity hospital network of ECLAMC examines around 200,000 births per year. All major and minor anomalies diagnosed at birth in infants weighing 500 g or more are registered according to a manual of procedures. The next non-malformed baby of the same sex born in the same hospital is selected as a control subject for each case. Thus, a one-to-one healthy control group matched by sex, time and place of birth is obtained. As a system of epidemic surveillance, ECLAMC systematically observes the fluctuations in the frequencies of different malformations and, in the case of an alarm for a probable epidemic of a given malformation, at a given moment, and given area, it acts to identify its cause. As termination of pregnancy has severe legal restrictions in South America, prevention of birth defects should concentrate on primary, preconceptional and tertiary measures. Tertiary measures aim to avoid complications of the affected patients from the medical, psychological, and social standpoints.

Keywords:
Birth defects, Birth prevalence, Environmental risk factors, Genetic risks, Hospital network, Molecular markers, Population structure, Risk factors, Secular trends, South American population
1.
Castilla EE, Lopez-Camelo JS: The surveillance of birth defects in South-America. I. The search for time clusters: Epidemics. Adv Mutag Res 1990;2:191–210.
2.
Czeizel AE, Intody Z, Modell B: What proportion of congenital abnormalities can be prevented? BMJ 1993;306:499–503.
3.
ICBDMS: Congenital Malformations Worldwide. Amsterdam, Elsevier, 1991.
4.
Castilla E, Czeizel A, Källén B, Mastroiacovo P, Oakley GP Jr, Takeshita K, De Wals P, Kuliev A: Methodology for birth defects monitoring. Birth Defects Original Article Ser 1986;22:1–43.
5.
Källén B, Knudsen LB, Mutchinick O, Mastroiacovo P, Lancaster PAL, Castilla EE, Robert E: Monitoring dominant germinal cell mutation using skeletal dysplasias registered in malformation registries. An international feasibility study. Int J Epidemiol 1993;22:107–115.
6.
Khoury MJ, Botto L, Waters GD, Mastroiacovo P, Castilla E, Erickson JD: Monitoring of new multiple congenital anomalies in the search for human teratogens. Am J Med Genet 1993;46:460–466.
7.
Robert E, Mutchinick O, Mastroiacovo P, Knudsen LB, Daltveit AK, Castilla EE, Lancaster PAL, Källén B, Cocchi G: An international collaborative study of the epidemiology of esophageal atresia or stenosis. Reprod Toxicol 1993;7:405–421.
8.
Liascovich R, Castilla EE, Rittler M: Consanguinity in South America: Demographic aspects. Hum Hered 2001;51:27–34.
9.
Rittler M, Liascovich R, Lopez-Camelo JS, Castilla EE: Parental consanguinity in specific types of congenital anomalies. Am J Med Genet 2001;102:36–43.
10.
Wyszynski DF, Beaty TH, Maestri NE: Genetics of nonsyndromic oral clefts revisited. Cleft Palate Craniofac J 1996;33:406–417.
11.
Schutte BC, Murray JC: The many faces and factors of orofacial clefts. Hum Mol Genet 1999;8:1853–1859.
12.
Roessler E, Belloni E, Gaudenz K, Jay P, Berta P, Scherer SW, Tsui LC, et al: Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat Genet 1996;14:357–360
13.
Bailliet G, Castilla EE, Adams JP, Orioli IM, Martínez-Marignac V, Richard S, Bianchi NO: Correlation between molecular and conventional genealogies in Aicuña: A rural population from Northwestern Argentina. Hum Hered 2001;51:150–159.
14.
Orioli IM, Castilla EE, Ming JE, Nazer J, Burle de Aguiar MJ, Llerena JC, Muenke M: Identification of novel mutations in SHH and ZIC2 in a South American (ECLAMC) population with holoprosencephaly. Hum Genet 2001;109:1–6.
15.
Orioli IM, Vieira AR, Castilla EE, Ming JE, Muenke M: Mutational analysis of the Sonic Hedgehog gene in 220 newborns with oral clefts in a South American (ECLAMC) population. Am J Med Genet 2002;108:12–15.
16.
Vieira AR , Karras JC, Orioli IM , Castilla EC, Murray JC: Genetic origins in a South American clefting population. Clin Genet 2002;62:458–463.
17.
Vieira AR, Orioli IM, Castilla EE, Cooper ME, Maratzita ML, Murray JC: MSX1 and TGFB3 contribute to clefting in South America. J Dent Res 2003;82:289–292.
18.
Jezewski P, Vieira AR, Nishimura C, Ludwig B, Johnson M, O’Brien SE, Daack-Hirsch S, Schultz RE, Weber A, Nepomucena B, Romitti PA, Christensen K, Orioli IM, Castilla EE, Machida J, Natsume N, Murray JC: Complete sequencing demonstrates a role for MSX1 in nonsyndromic cleft lip and palate. J Med Genet 2003;40:399–407.
19.
Vieira AR, Romitti PA, Orioli IM, Castilla EE: Inheritance of cleft palate in South America: Evidence for a major locus recessive. Orthod Craniofac Res 2003;6:83–87.
20.
Loffredo CA, Ewing CK: Use of stored newborn blood spots in research on birth defects: Variation in retrieval rates by type of defect and infant characteristics. Am J Med Genet 1997;69:85–88.
21.
Castilla EE, Lopez-Camelo JS, Campaña H: The altitude as a risk factor for congenital anomalies. Am J Med Genet 1999;86:9–14.
22.
Castilla EE, Orioli IM: Prevalence rates of microtia in South-America. Int J Epidemiol 1986;15:364–368.
23.
Monteleone-Neto R, Castilla EE, Paz JE: Hypospadias: An epidemiological study in Latin-America. Am J Med Genet 1981;10:5–19.
24.
Castilla EE, Cavalcanti DP, Dutra MG, Lopez-Camelo JS, Paz JE, Gadow EC: Limb reduction defects in South America. Br J Obstet Gynecol 1995;102:393–400.
25.
Castilla EE, Paz JE, Orioli-Parreiras IM: Syndactyly: Frequency of specific types. Am J Med Genet 1980;5:357–364.
26.
ICBDMS: Annual Report 2002. Rome, ICBDMS, 2002.
27.
Freire WB, Hertrampf E, Cortés F: Effect of folic acid fortification in Chile: Preliminary results. Eur J Pediatr Surg 2000;10(suppl 1):42–43.
28.
Castilla EE, Orioli IM, López-Camelo JS, Dutra MG, Nazer-Herrera J, Latin-American Collaborative Study of Congenital Malformations (ECLAMC): Preliminary data on changes in neural tube prevalence rates after folic acid fortification in South America. Am J Med Genet 2003;123A:123–128.
29.
Orioli IM, Lopez-Camelo JS, Dutra MG, Nazer-Herrera J, Castilla EE: Reduction in the birth prevalence rates of spina bifida after folic acid fortification: Change or trend? BMJ, in press.
30.
Castilla EE, Sod R: The surveillance of birth defects in South-America. II. The search for geographic clusters: Endemics. Adv Mutag Res 1990;2:211–230.
31.
Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, Cavalcanti DP, Correa-Neto J, Delgadillo JL, Dutra MG, Felix T, Giraldo A, Juarez N, Lopez-Camelo JS, Nazer J, Orioli IM, Paz JE, Pessoto MA, Pina-Neto JM, Quadrelli R, Rittler M, Rueda S, Saltos M, Sanchez O, Schuler L: Thalidomide, a current teratogen in South America. Teratology 1996;54:273–277.
32.
Orioli IM, Castilla EE: Epidemiological assessment of misoprostol teratogenicity. Br J Obstet Gynecol 2000;107:519–523.
33.
Grether JK, Harris JA, Hexter AC, Jackson RJ: Investigating Clusters of Birth Defects: Guidelines for a Systematic Approach. California Birth Defects Monitoring Program. Berkeley, 1988.
34.
Investigating Clusters of Non-Communicable Disease: Guidelines for Public Health Services. Wellington, Ministry of Health, Manatu Hauora, 1997.
35.
Ten-Kate LP: Epidemiology of potentially avoidable birth defects. Eur J Epidemiol 1986;2:320–325.
36.
Daly LE, Kirke PN, Molloy AM, et al: Folate levels and neural tube defects. Implication for prevention. JAMA 1995;274:1698–1702.
37.
Castilla EE, Lopez-Camelo JS, Paz JE, Orioli IM: Prevencion Primaria de los Defectos Congenitos, Dutra MG (ed). Rio de Janeiro, Fiocruz, 1997.
38.
Mercier B, Raguenes O, Estivill X, Morral N, Kaplan GC, McClure M, Grebe TA, Kessler D, Pignatti PF, Marigo C, et al: Complete detection of mutations in cystic fibrosis patients of Native American origin. Hum Genet 1994;94:629–632.
39.
Watkins WS, Bamshad M, Jorde LB: Population genetics of trinucleotide repeat polymorphisms. Hum Mol Genet 1995;4:1485–1491.
40.
Kunst CB, Zerylnick C, Karickhoff L, Eichler E, Bullard J, Chalifoux M, Holden JJ, Torroni A, Nelson DL, Warren ST: FMR1 in global populations. Am J Hum Genet 1996;58:513–522.
41.
Castilla EE, Adams JP: Migration and genetic structure in an isolated population in Argentina: Aicuña; in Adams JP (ed): Proceeding of: Convergent Questions in Genetics and Demography. Oxford, Oxford University Press, 1990, chap 4, pp 45–62.
42.
McKusick VA: Genetic studies in American inbred populations with particular reference to the Old Order Amish. Isr J Med Sci 1973;9:1276–1284.
43.
Monteleone Neto R, Castilla EE: Apparently normal frequency of congenital anomalies in the highly polluted town of Cubatão, Brazil. Am J Med Genet 1994;52:319–323.
44.
Rosano A, Smithells RW, Cacciani L, Botting B, Castilla E, Cornel M, Erickson D, Goujard J, Irgens L, Merlob P, Robert E, Siffel C, Stoll C, Sumiyoshi Y: Time trends in neural tube defects prevalence in relation to preventive strategies: An international study. J Epidemiol Community Health 1999;53:630–635.
45.
Rittler M, Orioli IM: Achondrogenesis type II with polydactyly. Am J Med Genet 1995;59:157–160.
46.
Salgado LJ, Ali CA, Castilla EE: Acrocallosal syndrome in a girl born to consanguineous parents. Am J Med Genet 1989;32:298–300.
47.
Rittler M, Paz JE, Castilla EE: VATERL: An epidemiologic analysis of risk factors. Am J Med Genet 1997;73:162–169.
48.
Castilla EE, Martinez Frias ML: Congenital healed cleft lip. Am J Med Genet 1995;58:106–112.
49.
Castilla EE, Dutra MG, Orioli-Parreiras IM: Epidemiology of congenital pigmented naevi. I. Incidence rates and relative frequencies. Br J Dermatol 1981;104:307–315.
50.
Castilla EE, Dutra MG, Orioli-Parreiras IM: Epidemiology of congenital pigmented naevi. II. Risk factors. Br J Dermatol 1981;104:421–427.
51.
Castilla EE: Twenty-five years working with birth defects in Latin-America. ECLAMC 1967–1992 (Latin-American Collaborative Study of Congenital Malformations). Proceedings of the III ASM International Symposium on Birth Defects, Roma, December 3–5, 1992. Milano, Associazione Italiana per lo Studio delle Malformazioni, 1992, pp 9–24.
52.
Castilla EE, Gomez MA, Lopez-Camelo JS, Paz JE: Frequency of first-cousin marriages from civil marriage certificates in Argentina. Hum Biol 1991;63:203–210.
53.
Orioli IM: Segregation distortion in the offspring of Afro-American fathers with postaxial polydactyly. Am J Hum Genet 1995;56:1207–1211.
54.
Vieira AR, Romitti PA, Orioli IM, Castilla EE: Complex segregation analysis of 1,792 cleft lip and palate families in South America: 1967–1997. Pesqui Odontol Bras, accepted.
55.
Orioli IM, Ribeiro MG, Castilla EE: Male to male transmission of supernumerary nipples. Am J Med Genet 1997;73:100.
56.
Feitosa MF, Castilla EE, Dutra MG, Krieger H: Lack of evidence of a major gene acting on postaxial polydactyly in South America. Am J Med Genet 1998;80:466–472.
57.
Castilla EE, Gomez MA, Lopez-Camelo JS, Paz JE: The Heritability of Malformations. Proceedings of the First International Meeting of the Genetic and Reproductive Epidemiology Research Society (GRERS). Milano, Ghedini, 1992, pp 17–26.
58.
Carothers AD, Castilla EE, Dutra MG, Hook EB: Search for ethnic, geographic and other factors in the epidemiology of Down syndrome in South America: Analysis of data from the ECLAMC project, 1967–1997. Am J Med Genet 2001;103:149–156.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.